ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 78 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,000 | -96.7% | 200 | -97.5% | 0.00% | – |
| Q1 2020 | $30,000 | -94.7% | 7,859 | -91.7% | 0.00% | – |
| Q4 2019 | $568,000 | +1059.2% | 94,276 | +1295.0% | 0.00% | – |
| Q3 2019 | $49,000 | -78.0% | 6,758 | -59.2% | 0.00% | – |
| Q2 2019 | $223,000 | -73.1% | 16,579 | -94.1% | 0.00% | -100.0% |
| Q4 2018 | $830,000 | +3092.3% | 279,500 | +8607.2% | 0.00% | – |
| Q3 2018 | $26,000 | -74.3% | 3,210 | -69.1% | 0.00% | – |
| Q2 2018 | $101,000 | -38.0% | 10,388 | -45.0% | 0.00% | – |
| Q1 2018 | $163,000 | -52.1% | 18,883 | -30.7% | 0.00% | – |
| Q4 2017 | $340,000 | -43.3% | 27,253 | -62.1% | 0.00% | – |
| Q3 2017 | $600,000 | -84.2% | 71,891 | -67.8% | 0.00% | -100.0% |
| Q2 2017 | $3,787,000 | +13925.9% | 223,208 | +5560.9% | 0.00% | – |
| Q2 2016 | $27,000 | +575.0% | 3,943 | +685.5% | 0.00% | – |
| Q1 2016 | $4,000 | -50.0% | 502 | -41.6% | 0.00% | – |
| Q4 2015 | $8,000 | -38.5% | 859 | -9.9% | 0.00% | – |
| Q3 2015 | $13,000 | – | 953 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ETF MANAGERS GROUP, LLC | 2,679,457 | $20,257,000 | 0.73% |
| Portolan Capital Management | 777,293 | $5,876,000 | 0.66% |
| CAMPBELL CAPITAL MANAGEMENT INC | 110,451 | $835,000 | 0.62% |
| ZEKE CAPITAL ADVISORS, LLC | 402,212 | $3,041,000 | 0.27% |
| Leap Investments LP | 46,084 | $348,000 | 0.17% |
| Bernardo Wealth Planning LLC | 26,419 | $199,000 | 0.14% |
| Claraphi Advisory Network, LLC | 14,744 | $111,000 | 0.07% |
| Sterling Investment Advisors, Ltd. | 11,000 | $83,000 | 0.04% |
| A.R.T. Advisors, LLC | 81,372 | $615,000 | 0.03% |
| Mirae Asset Global Investments Co., Ltd. | 544,408 | $4,116,000 | 0.03% |